Daily Sepsis Research Analysis
Today’s top sepsis research spans bench-to-bedside advances: a Cell Metabolism study identifies homocysitaconate as an anti-inflammatory metabolite with therapeutic effects in sepsis models; a pragmatic pediatric trial in Guatemala shows BCID2 rapid diagnostics plus stewardship shorten time-to-optimal therapy and reduce mortality in Gram-negative sepsis; and a multicenter analysis from CLOVERS supports the safety and feasibility of short-term peripheral vasopressors in early sepsis resuscitation
Summary
Today’s top sepsis research spans bench-to-bedside advances: a Cell Metabolism study identifies homocysitaconate as an anti-inflammatory metabolite with therapeutic effects in sepsis models; a pragmatic pediatric trial in Guatemala shows BCID2 rapid diagnostics plus stewardship shorten time-to-optimal therapy and reduce mortality in Gram-negative sepsis; and a multicenter analysis from CLOVERS supports the safety and feasibility of short-term peripheral vasopressors in early sepsis resuscitation.
Research Themes
- Immunometabolic regulation and novel anti-inflammatory metabolites in sepsis
- Rapid molecular diagnostics with antimicrobial stewardship in pediatric sepsis
- Vasopressor route safety and early resuscitation strategies
Selected Articles
1. Homocysitaconate controls inflammation through reshaping methionine metabolism and N-homocysteinylation.
This mechanistic study identifies homocysitaconate, a metabolite produced by AHCY-mediated adduction of homocysteine and itaconate, as a potent anti-inflammatory mediator. It inhibits MARS, reshapes methionine metabolism to curb N-homocysteinylation, promotes NLRP3 ubiquitination, and shows therapeutic efficacy in sepsis models.
Impact: Reveals a previously unrecognized immunometabolic node linking itaconate and homocysteine with direct therapeutic effects in sepsis models, opening a novel targetable pathway.
Clinical Implications: Although preclinical, augmenting homocysitaconate or modulating AHCY/MARS could represent a new anti-inflammatory strategy in sepsis, potentially complementing antibiotics and organ support.
Key Findings
- Homocysitaconate levels increased 152-fold during inflammation and exhibited anti-inflammatory activity.
- Mechanistically, homocysitaconate bound MARS at D312, inhibiting its function and reshaping methionine metabolism to brake N-homocysteinylation.
- The metabolite facilitated NLRP3 ubiquitination and showed therapeutic efficacy in sepsis, diet-induced inflammation, and colitis models.
- Endogenous synthesis could be boosted via NAD-linked pathways (as indicated), suggesting druggability.
Methodological Strengths
- Multisystem mechanistic dissection linking metabolite biogenesis, target engagement (MARS), and pathway effects (N-homocysteinylation, NLRP3).
- In vivo validation across multiple disease models including sepsis enhances translational relevance.
Limitations
- Preclinical models; human pharmacokinetics, safety, and optimal dosing remain unknown.
- Abstract truncation leaves details on NAD-linked augmentation and off-target effects unclear.
Future Directions: Define pharmacology, safety, and delivery strategies for homocysitaconate augmentation; validate immunometabolic signatures and target engagement in human sepsis; explore AHCY/MARS modulators.
Inflammation and its metabolic-network interactions generate novel regulatory molecules with translational implications. Here, we identify the immunometabolic crosstalk that generates homocysitaconate, a metabolite formed by homocysteine and itaconate adduction catalyzed by S-adenosyl-L-homocysteine hydrolase (AHCY). Homocysitaconate increases 152-fold during inflammation and exhibits anti-inflammatory effects. Mechanistically, homocysitaconate binds to the D312 residue of the pro-inflammatory protein methionyl-tRNA synthetase (MARS), inhibiting its function and reshaping methionine metabolism to feedback-brake the early activation of the N-homocysteinylation pathway. This metabolic switch facilitates NLR family pyrin domain-containing 3 (NLRP3) ubiquitination to control inflammation. Homocysitaconate demonstrates therapeutic effects in sepsis, high-fat-diet-induced inflammation, and colitis models. Boosting endogenous homocysitaconate synthesis through nicotinamide adenine dinucleotide (NAD
2. Evaluating the Clinical Impact of the BCID2 Panel and Antimicrobial Stewardship in Pediatric Bloodstream Infections: A Pragmatic Trial in Guatemala.
In a pragmatic pediatric trial in Guatemala, implementing the BCID2 panel with antimicrobial stewardship shortened time-to-optimal therapy and was associated with lower mortality in Gram-negative sepsis. This demonstrates the clinical utility of rapid multiplex diagnostics in low-resource settings.
Impact: Provides prospective, real-world evidence that integrating rapid molecular diagnostics with stewardship improves timeliness of therapy and survival in pediatric sepsis in an LMIC.
Clinical Implications: Hospitals can consider adopting BCID2 (or similar panels) with active stewardship to accelerate optimal therapy, particularly for Gram-negative bacteremia, potentially improving survival.
Key Findings
- BCID2 plus stewardship reduced median time-to-optimal antimicrobial therapy from 97.9 to 31.5 hours (P=0.03).
- Overall mortality trended lower with BCID2 (18% to 10%; P=0.08).
- In Gram-negative sepsis, mortality decreased from 25% (control) to 9.5% (BCID2), a 62% reduction (P=0.05).
- The study operated in a real-world LMIC setting with high AMR burden, enhancing generalizability to similar contexts.
Methodological Strengths
- Pragmatic design with contemporaneous control defined by time windows reflects real-world practice.
- Clinically meaningful outcomes (time-to-optimal therapy and mortality) with stewardship integration.
Limitations
- Non-randomized allocation based on timing may introduce selection bias and confounding.
- Single-country, single health system; high rate of coagulase-negative staphylococci may affect generalizability.
Future Directions: Conduct randomized or stepped-wedge cluster trials to confirm mortality benefits, evaluate cost-effectiveness, and define optimal stewardship workflows in diverse LMIC settings.
BACKGROUND: Multiplex polymerase chain reaction panels improve outcomes for bloodstream infections in high-income countries, but little is known in low- and middle-income countries, where there are high rates of antimicrobial resistance and mortality. METHODS: We conducted a pragmatic clinical trial in children at a public hospital in Guatemala comparing the impact of a multiplex polymerase chain reaction panel to conventional microbiologic methods. The BioFire Blood Culture Identification (BCID2) panel was performed with antimicrobial stewardship advice on positive blood cultures from midnight to 1 pm on weekdays as the intervention. Children with positive cultures outside these times served as the control group. Time-to-optimal antimicrobial therapy was the primary outcome measure. All-cause mortality was a secondary outcome. RESULTS: A total of 246 children were enrolled from April 2022 to October 2022: 135 in the BCID2 and 111 in the control group. The most common pathogens were coagulase-negative Staphylococcus (54%) and Klebsiella pneumoniae (11%). There was a significant reduction in median time-to-optimal antimicrobial therapy from 97·9 (0-252.3) hours to 31·5 (0-157.1) hours ( P = 0.03) in the control versus BCID2 groups. There was a trend for reduction in overall mortality from 18% (20 deaths) in the control to 10% (14 deaths) in the BCID2 group ( P =0.08). Subanalysis of children with Gram-negative sepsis revealed a 62% reduction in mortality with 14 (25%) deaths in the control group compared with 4 (9·5%) deaths in the BCID2 group ( P = 0.05). CONCLUSIONS: Use of BCID2 with antimicrobial stewardship significantly reduces time-to-optimal antimicrobial therapy in low- and middle-income countries like Guatemala, with a significant reduction in mortality due to Gram-negative bacteremia.
3. Peripheral Vasopressor Use in Early Sepsis-Induced Hypotension.
In this multicenter prospective analysis of CLOVERS, peripheral vasopressor initiation was common, had very low local complication rates (0.6%), and was associated with comparable 90-day mortality to central initiation. Findings support short-term peripheral vasopressors for early sepsis resuscitation.
Impact: Addresses a common, practice-critical question with multicenter data, potentially reducing delays from central line placement and minimizing procedure-related harms.
Clinical Implications: Clinicians can initiate vasopressors peripherally during early sepsis resuscitation with structured monitoring and timely reassessment, reserving central access for prolonged infusions or higher-dose requirements.
Key Findings
- Peripheral initiation occurred in 84.2% of eligible patients; study site drove route selection.
- Adjusted 90-day mortality was comparable for peripheral vs central initiation (aOR 0.67; 95% CI, 0.39–1.16).
- Peripheral complications were rare (0.6%) with no tissue injury, whereas early CVC complications occurred in 3.7%.
Methodological Strengths
- Large, multicenter, prospective cohort with adjusted analyses and clinically meaningful outcomes.
- Direct comparison of route-specific complications alongside mortality data.
Limitations
- Secondary analysis with nonrandomized route selection; unmeasured confounding likely.
- Practice variability across sites limits standardization of peripheral protocols.
Future Directions: Develop standardized protocols for peripheral vasopressors (catheter size, site, dilution, monitoring) and test them in pragmatic randomized or cluster trials.
IMPORTANCE: Evidence supporting the safety of infusing vasopressors through peripheral intravenous catheters (peripheral vasopressors) is largely derived from single-center studies, limiting generalizability. OBJECTIVE: To evaluate factors associated with vasopressor route selection and assess safety and clinical outcomes of peripheral vasopressor administration in early sepsis resuscitation. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study is a secondary analysis of the Crystalloid Liberal vs Early Vasopressors in Sepsis (CLOVERS) trial conducted in 60 US hospitals from March 2018 to February 2022. Patients in CLOVERS who received vasopressors within 24 hours of enrollment and did not have central venous access at enrollment were included. Data were analyzed from January 2023 to June 2025. EXPOSURE: Route of vasopressor initiation (central or peripheral). MAIN OUTCOMES AND MEASURES: The primary analysis evaluated the route of vasopressor initiation, while the secondary analysis assessed continuation of peripheral vasopressors beyond 6 hours. Univariable and multivariable analyses of factors associated with vasopressor route were conducted, as was a multivariable analysis to evaluate the association of route with outcomes, including 90-day mortality. Descriptive statistics were used to summarize 28-day peripheral vasopressor and central venous catheter (CVC) complications. RESULTS: Of 1563 patients in CLOVERS, 582 (37.2%) received vasopressors and met study inclusion criteria. Included patients had a median (IQR) age of 63 (52-72) years, and 267 (45.9%) were female, 96 (16.5%) were African American, 416 (71.5%) were White, and 70 (12.0%) were another race or had unreported race. Vasopressors were initiated via peripheral catheter in 490 patients (84.2%) and via central venous access in 92 patients (15.8%). Study site was the only factor independently associated with route of initiation (median odds ratio, 3.48; 95% CI, 1.57-5.38). In adjusted analyses, peripheral vs central initiation was associated with statistically comparable 90-day mortality (128 participants [26.1%] vs 34 participants [37.0%]; adjusted odds ratio, 0.67; 95% CI, 0.39-1.16). Peripheral vasopressors were continued beyond 6 hours in 333 of 490 patients (68.0%). Peripheral vasopressor complications were rare and low-grade (3 of 490 patients [0.6%]), with no cases of ulceration or tissue injury. In contrast, there were 14 complications from CVC placement occurring in 12 of 322 patients (3.7%) who had CVCs placed in the first 72 hours. CONCLUSIONS AND RELEVANCE: In this prospective cohort study of the CLOVERS trial, peripheral administration of vasopressors was common and was associated with low complication rates. These findings support the safety and feasibility of short-term peripheral vasopressor use in early sepsis resuscitation.